Form 4 for ONCO Onconetix, Inc.
Accepted 2023-05-11 00:00:00 ET · period of report 2023-05-09 · accession 0001213900-23-038666 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-05-11 | 2023-05-09 | ONCO | Henderson Erin | Chief Business Off | A - Grant | — | +150.0K | 174.8K | +606% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-05-09 | A | A | 150,000 | — | 174,752 | D | — | — | (F1) The restricted stock award was granted pursuant to the Blue Water Biotech, Inc. Amended and Restated 2022 Equity Incentive Plan. 50% of the stock award will vest on August 17, 2023; 25% of the award will vest on August 17, 2024; and the remaining 25% of the award will vest on August 18, 2025. |